The FDA has approved Fluad (MF59 adjuvanted seasonal influenza vaccine), from NVS Influenza Vaccines, the first seasonal influenza vaccine containing...
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Zoonotic Influenza Vaccine Seqirus, intended for the active immunisation against H5N1 subtype of Influenza A virus.
The FDA has approved FluMist Quadrivalent,from Medimmune a vaccine to prevent seasonal influenza in people ages 2 years through 49...
AstraZeneca announced that the European Commission (EC) has on 6 December 2013 granted Marketing Authorisation to Fluenz Tetra. Fluenz Tetra...
The FDA has approved a supplemental Biologics License Application for Fluzone High-Dose Quadrivalent (Influenza Vaccine), from Sanofi, for use in...
The European Commission has granted a marketing authorization for Supemtek, a quadrivalent (four-strain) recombinant influenza vaccine, from Sanofi, for the prevention of influenza in adults aged 18 years and older.
Roche has announced that the European Commission (EC) has approved Xofluza (baloxavir marboxil) in children aged one year and above for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza.
Seqirus announced that the FDA has approved Audenz (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted) to help protect individuals six months...
Roche announced that the FDA has approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours